Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  INC Research Holdings Inc    

INC RESEARCH HOLDINGS INC
Mes dernières consult.
Most popular
Report
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Rosen Law Firm Announces Investigation of Securities Claims Against INC Research Holdings, Inc. – INCR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 11:04pm CET

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of INC Research Holdings, Inc. (NASDAQ:INCR) resulting from allegations that INC Research may have issued materially misleading business information to the investing public.

On August 1, 2017, INC Research and inVentiv Health, Inc. (“inVentiv Health”) announced the completion of a merger between the two companies. On November 9, 2017, INC Research reported its first financial results after combining with inVentiv Health. The Company’s combined results were negatively impacted by merger-related expenses, an impairment charge and increased amortization expenses. On this news, shares of INC Research fell $16.35 per share or over 28% from its previous closing price to close at $41.15 per share on November 9, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by INC Research investors. If you purchased shares of INC Research, please visit the firm’s website at http://www.rosenlegal.com/cases-1236.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INC RESEARCH HOLDINGS INC
01/13 SYNEOS HEALTH : Merged INC Research, InVentiv Rebrand as Syneos
01/11 RESEARCH : Syneos Health Releases 2018 Commercial Trends Forecast
01/06 RESEARCH : and inVentiv merge to form Syneos Health
01/05 INC RESEARCH HOLDINGS INC : LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP ..
01/05 INC RESEARCH HOLDINGS INC : The Klein Law Firm Notifies Shareholders of a Class ..
01/05 INC RESEARCH HOLDINGS INC : Pomerantz Law Firm Investigates Claims On Behalf of ..
01/05 RESEARCH : inVentiv now Syneos Health
01/05 RESEARCH : inVentiv Health Becomes Syneos Health
01/04 INC RESEARCH HOLDINGS INC : Levi & Korsinsky, LLP Notifies Shareholders of Syneo..
01/04 INC Research/inVentiv Health Becomes Syneos Health™
More news
News from SeekingAlpha
01/03 INC Research CFO exiting post at April's end
2017 INC Research Holdings 2017 Q3 - Results - Earnings Call Slides
2017 INC Research's (INCR) CEO Alistair MacDonald on Q3 2017 Results - Earnings Ca..
2017 Midday Gainers / Losers
2017 INC Research misses by $0.08, misses on revenue
Financials ($)
Sales 2017 3 089 M
EBIT 2017 489 M
Net income 2017 13,1 M
Debt 2017 2 698 M
Yield 2017 -
P/E ratio 2017 136,33
P/E ratio 2018 41,11
EV / Sales 2017 3,64x
EV / Sales 2018 3,41x
Capitalization 8 535 M
Chart INC RESEARCH HOLDINGS INC
Duration : Period :
INC Research Holdings Inc Technical Analysis Chart | US45329R1095 | 4-Traders
Technical analysis trends INC RESEARCH HOLDINGS INC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 51,1 $
Spread / Average Target 25%
EPS Revisions
Sector and Competitors
1st jan.Capitalization (M$)
INC RESEARCH HOLDINGS INC-5.39%8 535
CELLTRION, INC.--.--%37 510
IQVIA HOLDINGS INC2.37%20 782
LONZA GROUP0.76%20 640
INCYTE CORPORATION-4.65%19 399
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 192